Targeting GLUT1 in acute myeloid leukemia to overcome cytarabine resistance

Haematologica. 2021 Apr 1;106(4):1163-1166. doi: 10.3324/haematol.2020.246843.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cytarabine* / therapeutic use
  • Glucose Transporter Type 1 / genetics
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics

Substances

  • Antimetabolites, Antineoplastic
  • Glucose Transporter Type 1
  • Cytarabine

Grant support

Funding: this work was supported by Swedish Research Council (2016-01319 and 2017-05816) and the Swedish Cancer Society (2017/307).